Latest stories on SPRC
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
Business Insider64 · neutralproduct/pr
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
Business Insider58 · neutralproduct/pr
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
GlobeNewswire58 · neutralproduct/pr
SciSparc Offers Inducement to Convert $2 Million Note Into Equity at $1.50 a Share
TipRanks28 · bearishgeneral
SciSparc Sets Strategic Pivot to Agentic AI for Cybersecurity and Finance
TipRanks63 · neutralproduct/pr
SciSparc (SPRC) pivots toward agentic AI, targeting cybersecurity and finance applications
October 15, 2026
MarketChameleon58 · neutralproduct/pr
Why is Scisparc stock surging today?
Investing.com Markets64 · neutralgeneral
SciSparc shifts focus toward Agentic AI-powered technologies
The Fly58 · neutralproduct/pr
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
GlobeNewswire63 · neutralproduct/pr
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
StockTitan63 · neutralproduct/pr
SciSparc’s CliniQuantum Hits Quantum-Enabled Breakthrough in Gene Analysis Speed
TipRanks73 · bullishproduct/pr
SciSparc Spotlights Three Published U.S. Patent Applications Linking PEA With LSD, Ketamine, and Ibogaine
September 24, 2026
MarketChameleon58 · neutralproduct/pr
SciSparc spotlights three published U.S. patent applications pairing PEA with LSD, ketamine, and ibogaine
September 23, 2026
MarketChameleon58 · neutralproduct/pr
SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine
The Fly63 · neutralproduct/pr
SciSparc’s NeuroThera Advances Enrollment in SCI-210 Autism Trial
TipRanks63 · neutralproduct/pr
SciSparc subsidiary provides update on SCI-210 trial enrollment
The Fly56 · neutralproduct/pr
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
StockTitan63 · neutralproduct/pr
Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment
The Fly56 · neutralproduct/pr
SciSparc Highlights NeuroThera-Clearmind MDMA-PEA Patent Milestone Amid New FDA Psychedelic Guidance
TipRanks63 · neutralproduct/pr
SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination
The Fly55 · neutralproduct/pr